Top ▲

β2-adrenoceptor

Click here for help

Target id: 29

Nomenclature: β2-adrenoceptor

Family: Adrenoceptors

Annotation status:  image of a green circle Annotated and expert reviewed  » Email us

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 413 5q32 ADRB2 adrenoceptor beta 2 101
Mouse 7 418 18 35.1 cM Adrb2 adrenergic receptor, beta 2 5
Rat 7 418 18q12.1 Adrb2 adrenoceptor beta 2 63
Previous and Unofficial Names Click here for help
ADRB2R | ADRBR | B2AR | beta-2 adrenergic receptor | beta-2 adrenoreceptor | Adrb-2 | beta 2-AR | Gpcr7 | adrenoceptor beta 2, surface | adrenergic receptor
Database Links Click here for help
Specialist databases
GPCRdb adrb2_human (Hs), adrb2_mouse (Mm), adrb2_rat (Rn)
Other databases
Alphafold
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the β2 adrenergic receptor-Gs protein complex
PDB Id:  3SN6
Resolution:  3.2Å
Species:  None
References:  148
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the human β2-adrenoceptor
PDB Id:  2R4R
Resolution:  3.4Å
Species:  Human
References:  147
Image of receptor 3D structure from RCSB PDB
Description:  Structure of β2-adrenoceptor bound to carazolol and an intracellular allosteric antagonist.
PDB Id:  5X7D
Ligand:  carazolol
Resolution:  2.7Å
Species:  Human
References:  114
Image of receptor 3D structure from RCSB PDB
Description:  Structure of β2 adrenoceptor bound to BI167107 and an engineered nanobody
PDB Id:  4LDE
Ligand:  BI-167107
Resolution:  2.79Å
Species:  Human
References:  149
Image of receptor 3D structure from RCSB PDB
Description:  Structure of the beta2 adrenergic receptor in the full agonist bound state
PDB Id:  6KR8
Resolution:  0.0Å
Species:  Human
References:  84
Image of receptor 3D structure from RCSB PDB
Description:  Structure of a nanobody-stabilized active state of the beta2 adrenoceptor
PDB Id:  3P0G
Resolution:  3.5Å
Species:  Human
References:  146
Image of receptor 3D structure from RCSB PDB
Description:  cryo-EM structure of the beta2-AR-mBRIL/1b3 Fab/Glue complex with a full agonist
PDB Id:  8JJL
Resolution:  3.2Å
Species:  Human
References:  69
Image of receptor 3D structure from RCSB PDB
Description:  Structure of beta2 adrenoceptor bound to carazolol and inactive-state stabilizing nanobody, Nb60
PDB Id:  5JQH
Resolution:  3.2Å
Species:  Human
References:  163
Image of receptor 3D structure from RCSB PDB
Description:  Structure of beta2 adrenergic receptor bound to BI167107, Nanobody 6B9, and a positive allosteric modulator
PDB Id:  6N48
Resolution:  3.2Å
Species:  Human
References:  116
Image of receptor 3D structure from RCSB PDB
Description:  XFEL beta2 AR structure by ligand exchange from Timolol to Propranolol.
PDB Id:  6PS5
Resolution:  2.9Å
Species:  Human
References:  86
Image of receptor 3D structure from RCSB PDB
Description:  Structure of human beta2 adrenergic receptor bound to constrained epinephrine
PDB Id:  7XKA
Resolution:  3.1Å
Species:  Human
References:  194
Image of receptor 3D structure from RCSB PDB
Description:  Dark structure of beta-2 Adrenergic receptor with photoazolol in Dark state recorded at SwissFEL
PDB Id:  9RKF
Resolution:  2.45Å
Species:  Human
References:  166
Associated Proteins Click here for help
Interacting Proteins
Name Effect References
β2-adrenoceptor 7,37,75,103,126
β1-adrenoceptor 107-108,126,197
β3-adrenoceptor 37
α1D-adrenoceptor 180
α2A-adrenoceptor 103
5-HT4 receptor 34
δ receptor 93,125
κ receptor 93
μ receptor 103
EP1 receptor 123
B2 receptor 70
CXCR4 106
CB1 receptor 83,103
mouse 71 (M71) Olfactory receptor 71
D1 receptor 103
OT receptor 192-193
epidermal growth factor receptor 121
GluA1 92
AT1 receptor 28,91
A1 receptor 45
Insulin receptor 170
Natural/Endogenous Ligands Click here for help
(-)-adrenaline
(-)-noradrenaline
Zn2+
Comments: Adrenaline exhibits greater potency than noradrenaline
Potency order of endogenous ligands (Human)
(-)-adrenaline > (-)-noradrenaline

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[125I]ICYP Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Partial agonist 10.6 – 11.4 pKd 87,119,154,173
⤷ pKd 10.6 – 11.4 [87,119,154,173]
[3H](-)CGP12177 Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Partial agonist 9.7 – 9.8 pKd 12,18,25
⤷ pKd 9.7 – 9.8 [12,18,25]
alprenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.8 – 9.5 pKd 12,14-15,23,79,167
⤷ pKd 8.8 – 9.5 [12,14-15,23,79,167]
cyanopindolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 10.5 – 10.7 pKi 13-14,153
⤷ pKi 10.5 – 10.7 [13-14,153]
carazolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.9 – 10.5 pKi 13-14,153
⤷ pKi 9.9 – 10.5 [13-14,153]
bucindolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 10.0 – 10.3 pKi 13-14,22-23,167
⤷ pKi 10.0 – 10.3 [13-14,22-23,167]
carvedilol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.4 – 10.6 pKi 12,14,17,43,143,160
⤷ pKi 9.4 – 10.6 [12,14,17,43,143,160]
vilanterol Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 9.0 – 9.4 pKi 143,158
⤷ pKi 9.0 – 9.4 [143,158]
CGP12177 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 8.4 – 9.8 pKi 12,14,23,79,143,155,158,167
⤷ pKi 8.4 – 9.8 [12,14,23,79,143,155,158,167]
oxprenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.8 – 9.4 pKi 13-14,23,167
⤷ pKi 8.8 – 9.4 [13-14,23,167]
pindolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 8.3 – 9.5 pKi 13-15,23,79,102,167
⤷ pKi 8.3 – 9.5 [13-15,23,79,102,167]
olodaterol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 8.7 pKi 143
⤷ pKi 8.7 [143]
SR59230A Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 7.2 – 9.3 pKi 13-14,43,79,177
⤷ pKi 7.2 – 9.3 [13-14,43,79,177]
salmeterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 6.8 – 9.6 pKi 12-13,25,50,79,87,143,155,158
⤷ pKi 6.8 – 9.6 [12-13,25,50,79,87,143,155,158]
labetalol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.0 – 8.3 pKi 12,14,22
⤷ pKi 8.0 – 8.3 [12,14,22]
zinterol Small molecule or natural product Click here for species-specific activity table Hs Agonist 8.0 pKi 13
⤷ pKi 8.0 [13]
indacaterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 7.4 – 7.9 pKi 30-31,143,158
⤷ pKi 7.4 – 7.9 [30-31,143,158]
clenbuterol Small molecule or natural product Click here for species-specific activity table Hs Agonist 7.2 – 7.9 pKi 13,25,97,167
⤷ pKi 7.2 – 7.9 [13,25,97,167]
procaterol Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 7.1 – 7.2 pKi 13,87
⤷ pKi 7.1 – 7.2 [13,87]
formoterol Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 5.6 – 8.6 pKi 13,79,87,143
⤷ pKi 5.6 – 8.6 [13,79,87,143]
ICI89406 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.8 – 7.1 pKi 12,14,112,129
⤷ pKi 6.8 – 7.1 [12,14,112,129]
L755507 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.8 pKi 13
⤷ pKi 6.8 [13]
L748337 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.5 – 7.1 pKi 13,43,177
⤷ pKi 6.5 – 7.1 [13,43,177]
ractopamine Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.7 – 6.9 pKi 13,97
⤷ pKi 6.7 – 6.9 [13,97]
Description: Inhibitory constant determined from a standard radioligand displacement assay using human β2-adrenoceptors expressed in Sf-9 cells and [3H]CGP1217 as tracer.
isoprenaline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Agonist 6.3 – 7.0 pKi 13,18,79,87,154,158,167
⤷ pKi 6.3 – 7.0 [13,18,79,87,154,158,167]
fenoterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Agonist 6.1 – 7.0 pKi 9,13,25,79,143
⤷ pKi 6.1 – 7.0 [9,13,25,79,143]
prenalterol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.4 pKi 87
⤷ pKi 6.4 [87]
Ro 363 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.8 – 6.2 pKi 130,168
⤷ pKi 5.8 – 6.2 [130,168]
xamoterol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.8 – 6.1 pKi 12,14,22,87,112,129
⤷ pKi 5.8 – 6.1 [12,14,22,87,112,129]
acebutolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 5.7 – 6.1 pKi 12,14,22
⤷ pKi 5.7 – 6.1 [12,14,22]
dobutamine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 5.8 – 5.9 pKi 13,87
⤷ pKi 5.8 – 5.9 [13,87]
(-)-adrenaline Small molecule or natural product Approved drug Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 5.4 – 6.2 pKi 13,25,57,79,89,167
⤷ pKi 5.4 – 6.2 [13,25,57,79,89,167]
salbutamol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 5.3 – 6.3 pKi 12-13,25,50,79,87,143,155,158,162
⤷ pKi 5.3 – 6.3 [12-13,25,50,79,87,143,155,158,162]
BRL37344 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.0 – 6.5 pKi 13,73,79,167
⤷ pKi 5.0 – 6.5 [13,73,79,167]
denopamine Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.3 – 5.8 pKi 13,87,155
⤷ pKi 5.3 – 5.8 [13,87,155]
terbutaline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 4.8 – 5.6 pKi 12-13,79,143
⤷ pKi 4.8 – 5.6 [12-13,79,143]
(-)-noradrenaline Small molecule or natural product Approved drug Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 4.6 – 5.4 pKi 13,57,79,87,167
⤷ pKi 4.6 – 5.4 [13,57,79,87,167]
carazolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.8 – 10.3 pEC50 13-14,153
⤷ pEC50 9.8 – 10.3 [13-14,153]
BI-167107 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 10.0 pEC50 78
⤷ pEC50 10.0 (EC50 1x10-10 M) [78]
Description: Determined in an intracellular cAMP accumulation assay in CHO-K1 cells expressing hβ2-AR
cyanopindolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 9.9 – 10.0 pEC50 13-14,153
⤷ pEC50 9.9 – 10.0 [13-14,153]
vilanterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 9.4 – 10.3 pEC50 142-143
⤷ pEC50 9.4 – 10.3 [142-143]
olodaterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 9.4 – 10.0 pEC50 36,143
⤷ pEC50 9.4 – 10.0 [36,143]
bucindolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 9.4 – 9.8 pEC50 13-14,23
⤷ pEC50 9.4 – 9.8 [13-14,23]
zinterol Small molecule or natural product Click here for species-specific activity table Hs Agonist 9.5 pEC50 13
⤷ pEC50 9.5 [13]
pindolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.1 – 9.7 pEC50 13-14,19,23-24
⤷ pEC50 9.1 – 9.7 [13-14,19,23-24]
formoterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 8.6 – 10.1 pEC50 4,13,25,30,143
⤷ pEC50 8.6 – 10.1 [4,13,25,30,143]
oxprenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.1 – 9.6 pEC50 13-14,23,167
⤷ pEC50 9.1 – 9.6 [13-14,23,167]
salmeterol Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 8.2 – 10.4 pEC50 13,21,25,30,50,143,155
⤷ pEC50 8.2 – 10.4 [13,21,25,30,50,143,155]
carvedilol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.1 – 9.4 pEC50 14,19
⤷ pEC50 9.1 – 9.4 [14,19]
clenbuterol Small molecule or natural product Click here for species-specific activity table Hs Agonist 9.2 pEC50 13
⤷ pEC50 9.2 [13]
alprenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.5 – 9.7 pEC50 14,19,21,23
⤷ pEC50 8.5 – 9.7 [14,19,21,23]
CGP12177 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 8.3 – 9.7 pEC50 14,18,21,23-24,155
⤷ pEC50 8.3 – 9.7 [14,18,21,23-24,155]
indacaterol Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 8.1 – 9.3 pEC50 30,143
⤷ pEC50 8.1 – 9.3 [30,143]
labetalol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.1 – 8.9 pEC50 14,19,21
⤷ pEC50 8.1 – 8.9 [14,19,21]
procaterol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 8.4 pEC50 13
⤷ pEC50 8.4 [13]
isoprenaline Small molecule or natural product Approved drug Click here for species-specific activity table Hs Agonist 7.8 – 8.8 pEC50 13,18,20-21,50
⤷ pEC50 7.8 – 8.8 [13,18,20-21,50]
SR59230A Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 8.1 – 8.4 pEC50 13-14,177
⤷ pEC50 8.1 – 8.4 [13-14,177]
fenoterol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Agonist 6.1 – 9.6 pEC50 13,50,143,177
⤷ pEC50 6.1 – 9.6 [13,50,143,177]
ractopamine Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 7.6 – 7.8 pEC50 13,50
⤷ pEC50 7.6 – 7.8 [13,50]
(-)-adrenaline Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 6.8 – 8.4 pEC50 13,20,50
⤷ pEC50 6.8 – 8.4 [13,20,50]
salbutamol Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 6.3 – 8.7 pEC50 13,18,20-21,25,50,143,155
⤷ pEC50 6.3 – 8.7 [13,18,20-21,25,50,143,155]
terbutaline Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 6.6 – 8.3 pEC50 13,20,143
⤷ pEC50 6.6 – 8.3 [13,20,143]
ICI89406 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 7.2 – 7.3 pEC50 14,129
⤷ pEC50 7.2 – 7.3 [14,129]
L755507 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 7.1 pEC50 13
⤷ pEC50 7.1 [13]
BRL37344 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.9 pEC50 13
⤷ pEC50 6.9 [13]
ATR-258 Small molecule or natural product Hs Biased agonist 6.9 pEC50
⤷ pEC50 6.9 (EC50 1.35x10-7 M)
Description: Reported as agonist-induced recruitment of GRK2, determined in an ebBRET assay
xamoterol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.2 – 6.5 pEC50 14,129
⤷ pEC50 6.2 – 6.5 [14,129]
dobutamine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 6.3 pEC50 13,50
⤷ pEC50 6.3 [13,50]
acebutolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 6.0 – 6.5 pEC50 14,19
⤷ pEC50 6.0 – 6.5 [14,19]
denopamine Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.7 – 6.4 pEC50 13,155
⤷ pEC50 5.7 – 6.4 [13,155]
(-)-noradrenaline Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 5.4 – 6.4 pEC50 13,50
⤷ pEC50 5.4 – 6.4 [13,50]
L748337 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist <5.0 – 6.4 pEC50 13,177
⤷ pEC50 6.4 [13,177]
pEC50 <5.0 (EC50 >1x10-5 M)
mirabegron Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 5.0 – 6.2 pEC50 51,175,195
⤷ pEC50 5.0 – 6.2 [51,175,195]
solabegron Small molecule or natural product Click here for species-specific activity table Hs Agonist <5.0 – 5.9 pEC50 182,195
⤷ pEC50 5.9 [182,195]
pEC50 <5.0 (EC50 >1x10-5 M)
mirabegron Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Rn Agonist 5.0 pEC50 51
⤷ pEC50 5.0 [51]
vibegron Small molecule or natural product Approved drug Click here for species-specific activity table Hs Agonist <5.0 pEC50 195
⤷ pEC50 <5.0 (EC50 >1x10-5 M) [195]
View species-specific agonist tables
Agonist Comments
Selective β2-AR agonists are one of the most successful groups of drugs for treatment of asthma and COPD [26,35]. The β2-AR selective agonists salbutamol, terbutaline and fenoterol (SABAs) are short acting (4-6 hours) partial agonists with few side effects but good efficacy in lung due to high β2-AR expression in bronchial smooth muscle and are usually given by inhalation to provide short-term relief without desensitisation. Salmeterol and formoterol are long acting β2-AR selective agonists (LABAs) and indacaterol, olodaterol and vilanterol are ultra long acting β-AR agonists (ultra-LABAs) [26,35]. BRL37344 is classified as a β3-AR selective agonist (rodent selective) but also has significant actions at β2-AR [133].
β2-AR agonists also promote growth of skeletal muscle [99] an effect that has been utilised to promote increased weight and leanness in livestock. Clenbuterol is included on the World Anti-Doping Authority's list of banned substances due to its popularity as a drug used by bodybuilders and for weight loss. There is evidence however to suggesting that clenbuterol and some other β2-AR agonists, when used under controlled conditions, may have potential for the treatment of both type II diabetes [95,133,152] and obesity [132]. The dual β2-/β3-AR agonist BRL37344 that is a weak partial agonist for cAMP accumulation when acting at β2-AR in skeletal muscle acts as a full agonist for glucose uptake without recruitment of β-arrestin or desensitisation [73].
Biased agonism (or ligand directed signalling) has been reported at the β2-AR such that the responses observed cannot be explained by a linear signalling cascade. It is possible that signalling bias is a tissue-dependent phenomenon and depends on the precise scaffold and signalling molecules expressed in that tissue. For example, GRK2 is essential for β2-AR mediated glucose uptake into skeletal muscle and GRK-biased β2-AR agonists have potential for the treatment of diabetes and obesity [132]
Clinical uses: β2-AR agonists are widely used to treat asthma and COPD. Adrenaline is used as a bolus injection in cardiac arrest, anaphylaxis and as an intravenous infusion for shock.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
carvedilol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 10.6 pA2 17
⤷ pA2 10.6 [17]
bunolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 10.3 pA2 23
⤷ pA2 10.3 [23]
carteolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 9.9 pA2 23
⤷ pA2 9.9 [23]
CGP12177 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 8.9 – 10.0 pA2 18,24
⤷ pA2 8.9 – 10.0 [18,24]
ICI118551 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.8 – 10.0 pA2 18-20,23-24,177
⤷ pA2 8.8 – 10.0 [18-20,23-24,177]
propranolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.7 – 9.6 pA2 20,23-24
⤷ pA2 8.7 – 9.6 [20,23-24]
SR59230A Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.4 pA2 177
⤷ pA2 8.4 [177]
nebivolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.9 pA2 17
⤷ pA2 7.9 [17]
L748337 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 7.1 pA2 177
⤷ pA2 7.1 [177]
bisoprolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.8 – 6.9 pA2 17,24
⤷ pA2 6.8 – 6.9 [17,24]
CGP20712A Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.4 – 6.1 pA2 23-24,177
⤷ pA2 5.4 – 6.1 [23-24,177]
atenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 4.8 – 6.2 pA2 20
⤷ pA2 4.8 – 6.2 [20]
[125I]ICYP Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Partial agonist 10.6 – 11.4 pKd 87,119,154,173
⤷ pKd 10.6 – 11.4 It is necessary to use an excess of a β1-adrenoceptor-selective ligand such as CGP20712A in combination with this radioligand in order to allow visualisation of β2-adrenoceptor binding in native tissues. [87,119,154,173]
[3H]dihydroalprenolol Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Antagonist 10.1 pKd 173
⤷ pKd 10.1 [173]
[3H](-)CGP12177 Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Partial agonist 9.7 – 9.8 pKd 12,14,17-18,112
⤷ pKd 9.7 – 9.8 [12,14,17-18,112]
[3H](-)CGP12177 Small molecule or natural product Ligand is labelled Ligand is radioactive Rn Partial agonist 9.6 pKd 17
⤷ pKd 9.6 [17]
cyanopindolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 10.4 – 10.7 pKi 13-14,153
⤷ pKi 10.4 – 10.7 [13-14,153]
7-methylcyanopindolol Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 10.4 pKi 153
⤷ pKi 10.4 [153]
carazolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.9 – 10.5 pKi 13-14,153
⤷ pKi 9.9 – 10.5 [13-14,153]
bunolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 10.1 pKi 14,23
⤷ pKi 10.1 [14,23]
bucindolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 10.0 – 10.2 pKi 13-14,22-23
⤷ pKi 10.0 – 10.2 [13-14,22-23]
carvedilol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 9.4 – 10.6 pKi 12,14,17,22,43,143,160
⤷ pKi 9.4 – 10.6 [12,14,17,22,43,143,160]
timolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 9.7 – 10.0 pKi 12,14,16
⤷ pKi 9.7 – 10.0 [12,14,16]
carteolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 9.7 – 9.8 pKi 14,23
⤷ pKi 9.7 – 9.8 [14,23]
carvedilol Small molecule or natural product Approved drug Click here for species-specific activity table Rn Partial agonist 9.7 pKi 17
⤷ pKi 9.7 [17]
ICI118551 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 9.2 – 9.5 pKi 14,16-18,22-23,41,143,153,177
⤷ pKi 9.2 – 9.5 [14,16-18,22-23,41,143,153,177]
ICI118551 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Rn Antagonist 9.3 pKi 13
⤷ pKi 9.3 [13]
oxprenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 9.0 – 9.4 pKi 14,23
⤷ pKi 9.0 – 9.4 [14,23]
propranolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 9.0 – 9.3 pKi 12,14-16,119,140,143,160
⤷ pKi 9.0 – 9.3 [12,14-16,119,140,143,160]
CGP12177 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 8.4 – 9.8 pKi 12,14,18,23,143,167
⤷ pKi 8.4 – 9.8 [12,14,18,23,143,167]
bupranolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 8.3 – 9.9 pKi 12,14,43,119
⤷ pKi 8.3 – 9.9 [12,14,43,119]
alprenolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 9.0 – 9.2 pKi 12,14-15,23
⤷ pKi 9.0 – 9.2 [12,14-15,23]
pKi 9.0 [12]
pindolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 8.6 – 9.5 pKi 13-15,23,167
⤷ pKi 8.6 – 9.5 [13-15,23,167]
SR59230A Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.1 – 9.3 pKi 13-14,43,177
⤷ pKi 8.1 – 9.3 [13-14,43,177]
propafenone Small molecule or natural product Approved drug Click here for species-specific activity table Rn Antagonist 8.6 pKi 124
⤷ pKi 8.6 [124]
labetalol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 8.0 – 8.3 pKi 12,14,22
⤷ pKi 8.0 – 8.3 [12,14,22]
nadolol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 7.0 – 8.5 pKi 14,43
⤷ pKi 7.0 – 8.5 [14,43]
NIP Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.5 pKi 119
⤷ pKi 7.5 [119]
nebivolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 6.9 – 7.9 pKi 13,22,112
⤷ pKi 6.9 – 7.9 [13,22,112]
Description: Radioligand binding
betaxolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.6 – 8.2 pKi 12,14,16,112,119,160
⤷ pKi 6.6 – 8.2 [12,14,16,112,119,160]
bevantolol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 7.3 pKi 14
⤷ pKi 7.3 [14]
L748337 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.5 – 7.1 pKi 12,43,177
⤷ pKi 6.5 – 7.1 [12,43,177]
sotalol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 6.7 – 6.9 pKi 12,14
⤷ pKi 6.7 – 6.9 [12,14]
metoprolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.3 – 6.9 pKi 12,14,119,160
⤷ pKi 6.3 – 6.9 [12,14,119,160]
prenalterol Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.4 pKi 87
⤷ pKi 6.4 [87]
bisoprolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.3 – 6.5 pKi 14,17,22,112,160,174
⤷ pKi 6.3 – 6.5 [14,17,22,112,160,174]
NIHP Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.0 pKi 119
⤷ pKi 6.0 [119]
acebutolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 5.7 – 6.1 pKi 12,14,22
⤷ pKi 5.7 – 6.1 [12,14,22]
bisoprolol Small molecule or natural product Approved drug Click here for species-specific activity table Rn Antagonist 5.8 pKi 17
⤷ pKi 5.8 [17]
CGP20712A Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.4 – 6.1 pKi 12,14,16-17,22-23,41,43,119,143,153,177
⤷ pKi 5.4 – 6.1 [12,14,16-17,22-23,41,43,119,143,153,177]
atenolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.1 – 6.0 pKi 12,14,119,160
⤷ pKi 5.1 – 6.0 [12,14,119,160]
esmolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.2 – 5.7 pKi 16,112,135
⤷ pKi 5.2 – 5.7 [16,112,135]
NDD-825 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.3 – 5.6 pKi 14,17
⤷ pKi 5.3 – 5.6 [14,17]
LK 204-545 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.3 pKi 17,119
⤷ pKi 5.3 [17,119]
CGP20712A Small molecule or natural product Click here for species-specific activity table Rn Antagonist 5.2 pKi 17
⤷ pKi 5.2 [17]
practolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.0 – 5.2 pKi 12,14,119
⤷ pKi 5.0 – 5.2 [12,14,119]
NDD-713 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.1 pKi 17
⤷ pKi 5.1 [17]
NDD-825 Small molecule or natural product Click here for species-specific activity table Rn Antagonist 4.9 pKi 17
⤷ pKi 4.9 [17]
landiolol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 4.7 – 5.0 pKi 14,135
⤷ pKi 4.7 – 5.0 [14,135]
LK 204-545 Small molecule or natural product Rn Antagonist 4.8 pKi 17
⤷ pKi 4.8 [17]
NDD-713 Small molecule or natural product Click here for species-specific activity table Rn Antagonist 4.7 pKi 17
⤷ pKi 4.7 [17]
View species-specific antagonist tables
Antagonist Comments
The approved drug propranolol is categorised as a non-selective β-AR antagonist but is slightly selective for β2-AR and has very low affinity for β3-AR. Propranolol can also behave as a biased agonist acting as an inverse agonist decreasing cAMP whilst stimulating β-arrestin, ERK1/2 phosphorylation and gene transcription [10,19]. The clinical implications of biased signalling are currently uncertain as biased and unbiased β-AR antagonists appear equally effective in clinical settings (e.g. bisoprolol, metoprolol and carvedilol in heart failure). Carvedilol is a non-selective β-AR and α1-AR antagonist used to treat cardiac failure. Carvedilol has been suggested to be a β-arrestin biased agonist [189] but this property has been challenged [32] with evidence supporting low efficacy activation of Gs coupled β2-ARs as the explanation. Several 'cardioselective' or β1-AR selective antagonists such as atenolol and metoprolol have appreciable affinity for β2-AR. Antagonists that display partial agonist activity at β2-AR include pindolol, carazolol, bucindolol, nebivolol and carvedilol [13] particularly in assays where there is significant receptor reserve or receptor over-expression. ICI118551 is the most selective β2-AR antagonist available but is only used in in vitro studies where it displays ~300 fold selectivity vs. the other 8 adrenoceptor subtypes [12]. Although often described as a β3-AR selective antagonist, SR59230A has little selectivity and has high affinity for β2-AR [127]. Propafenone mainly blocks voltage gated Na+ channels (see Voltage-gated sodium channels in the Ion Channels section of this website) but is also a weak β-AR antagonist. Some cell systems (e.g. HEK cells) commonly used to study the pharmacology of β-AR subtypes express functionally active β2-AR.
Clinical uses: Selective β2-AR antagonists have no current clinical uses, but effects of several β-AR antagonists used clinically (see β1-AR) also likely involve β2-AR (e.g. migraine, portal hypertension, anxiety, glaucoma, thyrotoxicosis, infantile haemangioma). In cancer, there is increasing interest in the potential of β1- and β2-AR antagonists to reduce both the growth of the primary tumour and reduce metastatic spread with evidence from laboratory and epidemiological studies that propranolol and carvedilol may be effective, particularly with regard to β2-AR antagonism [100,104,159,181].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
Zn2+ Click here for species-specific activity table Ligand is endogenous in the given species Hs Positive 5.3 pKi 171-172
⤷ pKi 5.3 [171-172]
Zn2+ Click here for species-specific activity table Ligand is endogenous in the given species Hs Negative 3.3 pKi 171-172
⤷ pKi 3.3 [171-172]
AS408 Small molecule or natural product Ligand has a PDB structure N/A - - - 115
⤷ [115]
compound 6 [PMID: 29769246] Small molecule or natural product Hs Positive - - 138
⤷ cooperativity [138]
View species-specific allosteric modulator tables
Allosteric Modulator Comments
Zn2+ appears to have both positive and negative effects on agonist affinity. At low concentrations it appears to enhance agonist affinity and agonist-stimulated cAMP accumulation. At high concentrations Zn2+ inhibits agonist binding but slows antagonist dissociation [171-172]. Cmpd-6 is a positive allosteric modulator of the pharmacological activity of carvedilol at the β2-AR [138].
Immunopharmacology Comments
β2-ARs are expressed on innate and adaptive immune cells of humans and rodents, and are reported to have an immuno-modulating effect [52].
There is a large literature on the role of autoantibodies to β2-AR associated with a variety of disease processes [38,44,80,82,188].
Cell Type Associations
Immuno Cell Type:  B cells
Cell Ontology Term:   B cell (CL:0000236)
Comment:  B cells from patients with rheumatoid arthritis express lower levels of β2-ARs compared with healthy subjects.
References:  11
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Comment:  β2-AR agonist-exposed mature dendritic cells have a reduced ability to cross-present protein antigens while retaining exogenous peptide presentation capability. This effect is mediated through a Gi/o inhibitory pathway.
References:  76
Immuno Cell Type:  T cells
Cell Ontology Term:   CD8-positive, alpha-beta T cell (CL:0000625)
regulatory T cell (CL:0000815)
Comment:  Activation of β2-ARs enhances retention-promoting signals through CCR7 and CXCR4 and inhibits lymphocyte (T cells and other lymphocyte lineages) egress from lymph nodes. In models of T cell-mediated inflammatory diseases, β2-AR-mediated signals inhibit lymph node egress of antigen-primed T cells and reduce their recruitment into peripheral tissues [134].CD8+ T cells (CL:0000625): CD8+ T cells from patients with rheumatoid arthritis express lower levels of β2-ARs compared with healthy subjects [11].
Treg cells (CL:0000815): β2-AR agonist increases Treg-cell suppressive function associated with decreased IL-2 mRNA levels in responder CD4+ T cells and improved Treg-cell-induced conversion of CD4+ Foxp3- cells into Foxp3+ induced Treg cells [67].
References:  11,67
Immuno Cell Type:  Mast cells
Cell Ontology Term:   mast cell (CL:0000097)
Comment:  Mast cell histamine release was increased in coculture with human airways smooth muscle cells and this was enhanced by β2-AR agonists. Inhibition of mast cell mediator release by β2-AR-agonists was reduced in coculture. β2-AR agonists did not prevent smooth muscle cell contraction when mast cells were present, but this was reversed by corticosteroids.
References:  110
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   macrophage (CL:0000235)
monocyte (CL:0000576)
Comment:  Monocytes (CL:0000576): Monocytes from patients with rheumatoid arthritis express lower levels of β2-ARs compared with healthy subjects [11]. Monocytes from high-fat diet-induced obese mice presented higher expression levels of pro-inflammatory cytokines and a higher % of monocytes with a pro-inflammatory phenotype than those from lean animals. β2-AR stimulation induced a shift towards an anti-inflammatory activity profile and phenotype in obese mice, whereas it induced a shift towards a pro-inflammatory activity profile and phenotype in lean mice [58]. Treatment of monocytes with the β2-AR agonist clenbuterol inhibits differentiation into dendritic cells, reduces the % of CD1a+ immature DCs, while increasing the frequency of monocytes retaining CD14 surface expression [62].
Macrophages (CL:0000235): Immune cell β2-ARs are important for proinflammatory macrophage infiltration to the heart in a chronic isoprenaline administration model of heart failure. Mice lacking immune cell β2-AR have decreased proinflammatory macrophage infiltration to the heart, decreased cardiac injury and cardiomyocyte death, decreased interstitial fibrosis and hypertrophy and improved function [176].
References:  11,58,62,176
Immuno Process Associations
Immuno Process:  Antigen presentation
GO Annotations:  Associated to 1 GO processes
GO:0006898 receptor-mediated endocytosis IDA
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gs family Adenylyl cyclase stimulation
Comments:  Stimulation of adenylate cyclase (AC) causes the conversion of ATP into cAMP. This activates protein kinase A, which in turn phosphorylates several substrates, for example L-type Ca2+ channels. In skeletal muscle cAMP signalling is associated with mTORC2 activation that promotes GLUT4 translocation and increased glucose uptake.
References:  111,156,164,187
Secondary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gi/Go family Adenylyl cyclase inhibition
Guanylate cyclase stimulation
Comments:  Adenylyl cyclase inhibition reduces the conversion of ATP to cAMP. Stimulation of guanylyl cyclase (GC) causes an increase in cGMP levels, and subsequent activation of protein kinase G.
References:  111,190
Tissue Distribution Click here for help
Macrophages,lymphocytes, dendritic cells (human, rat and mouse)
Species:  Human
Technique:  Reduction of inflammatory cytokines
References:  88,157
Heart: right atrial appendage, left atrial free wall, left ventricular papillary muscle and pericardium, atrioventricular node, bundle of His, interatrial and interventricular septa, right atrium, left ventricular free wall, right ventricular free wall, right atrium from an area near the atrioventricular node and cardiac nerves. Intimal surface of coronary arteries.
Species:  Human
Technique:  Autoradiography
References:  41,53,169
55 organs and tissues.
Species:  Human
Technique:  RNA expression.
References:  29
Heart
Species:  Human
Technique:  Radioligand binding
References:  27,39,64,165,183
Brain
Species:  Human
Technique:  Radioligand binding
References:  94,120,139,151
White, brown and brite fat (human, rat and mouse)
Species:  Human
Technique:  mRNA expression
References:  55
Brain: medial prefrontal cortex.
Species:  Mouse
Technique:  Immunohistochemistry in GABAergic interneurons in medial prefrontal cortex, including parvalbumin (PV)-, calretinin (CR)-, calbindin D-28k (CB)-, somatostatin (SST)- and reelin-immunoreactive (ir) interneurons. β2-AR most likely in SSTR-ir neurons.
References:  117
Lung >> skeletal muscle > spleen > kidney > heart > brain > liver.
Species:  Mouse
Technique:  in situ hybridisation.
References:  6
Lung >> spleen > kidney > heart > brain > skeletal muscle > liver.
Species:  Mouse
Technique:  Radioligand binding.
References:  6
Skeletal muscle
Species:  Rat
Technique:  Radioligand binding
References:  98,136
Internal anal sphincter (IAS) smooth muscle.
Species:  Rat
Technique:  Western blotting.
References:  111
Brain: Caudate, cortex, cerebellum, hippocampus, diencephalon.
Species:  Rat
Technique:  Radioligand binding.
References:  128
Diabetic heart.
Species:  Rat
Technique:  Radioligand binding, western blot, mRNA.
References:  54,72
Subcellular distribution in ventricular myocytes.
Species:  Rat
Technique:  Ventricular myocytes and detubulated myocytes: Ca2+ transients and cell shortening: β2-AR at surface sarcolemma.
References:  48
Subcellular distribution in heart (rat and mouse)
Species:  Rat
Technique:  FRET based cAMP signalling, scanning ion conductance microscopy (SCIM)
References:  65,191
Lung > heart.
Species:  Rat
Technique:  Radioligand binding.
References:  128
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Measurement of cAMP levels in rat heart and lung tissue.
Species:  Rat
Tissue:  Heart and lung.
Response measured:  cAMP accumulation.
References:  128
Measurement of cAMP levels in human lung epithelial cell lines.
Species:  Human
Tissue:  Calu-3 and 16HBE14o- cell lines.
Response measured:  cAMP accumulation.
References:  1
Measurement of cAMP levels in a human macrophage cell line.
Species:  Human
Tissue:  U937 cells.
Response measured:  cAMP accumulation.
References:  88
Measurement of cAMP levels in Sf9 insect cells transfected with the human β2-adrenoceptor.
Species:  Human
Tissue:  Sf9 cells.
Response measured:  cAMP accumulation.
References:  156
The trachea of an anesthetized mouse is intubated and airway resistance is measured in response to intravenously injected agonists.
Species:  Mouse
Tissue:  Lung.
Response measured:  Decrease in airway resistance.
References:  42
Measurement of cAMP and Ca2+ levels in CHW fibroblast cells endogenously expressing Gs, AC and PKA and transfected with both the β2-adrenoceptor and the L-type Ca2+ channel.
Species:  Human
Tissue:  CHW-1102 fibroblast cells.
Response measured:  PTX-insensitive cAMP and Ca2+ accumulation.
References:  196
Measurement of LPS-induced cytokine release (TNFα and Il-10) from human U937 macrophage cells when treated with a β2-adrenoceptor agonist.
Species:  Human
Tissue:  U937 cells.
Response measured:  Inhibition of TNFα release, stimulation of Il-10 release.
References:  88
Measurement of cAMP levels in CHO-K1 cells expressing the human β2 receptor.
Species:  Human
Tissue:  CHO-K1 cells.
Response measured:  cAMP accumulation.
References:  154
β-arrestin recruitment.
Species:  Human
Tissue:  HEK293 cells.
Response measured:  Interaction monitored using BRET between β-arrestin2-GFP10 and β2-AR-RlucII.
References:  85
cAMP production in skeletal muscle.
Species:  Rat
Tissue:  L6 skeletal muscle cells.
Response measured:  cAMP accumulation using antibody-based flashplate assay.
References:  137
Measurement of cAMP levels in rat heart and lung tissue.
Species:  Rat
Tissue:  Heart and lung.
Response measured:  cAMP accumulation.
References:  128
Measurement of cAMP levels in CHO-K1 cells expressing the human β2 receptor.
Species:  Human
Tissue:  CHO-K1 cells.
Response measured:  Whole cell binding using [3H]CGP12177, cAMP accumulation.
References:  13
β2-adrenoceptor agonist profiling reveals biased signalling phenotypes for the β2-adrenoceptor with possible implications for the treatment of asthma.
Species:  Human
Tissue:  Glo-sensor cAMP accumulation, pathhunter β-arrestin recruitment, BRET G protein recruitment, ERK1/2 phosphorylation, receptor internalization and endosomal localisation.
Response measured:  HEK293 cells expressing human β2-AR.
References:  50
Measurement of cAMP levels in HEK-293 cell lines expressing the Glosensor (Promega) cAMP reporter, the ICUE2 cAMP reporter and the human β2-AR .
Species:  Human
Tissue:  HEK293 cells.
Response measured:  cAMP accumulation measured using chemiluminescence-based cAMP biosensor.
References:  3
GTPase activity.
Species:  Human
Tissue:  HEK293 cells.
Response measured:  GTP hydrolysis using chemiluminescence-based GTPase-Glo Assay (Promega)
References:  3
β-arrestin recruitment and endocytosis.
Species:  Human
Tissue:  HEK293 cells.
Response measured:  Recruitment monitored using PathHunter, a chemiluminescence-based enzyme fragment complementation assay: endocytosis measured by active endocytosis assay (DiscoverX).
References:  3
Intracellular Ca2+ mobilisation involving PLC and IP3 but not cAMP, Gαs or Gαi.
Species:  Human
Tissue:  HEK293 cells endogenously expressing β2-AR.
Response measured:  Fluorescence-based Ca2+ flux assays
References:  59
Receptor heteromer formation.
Species:  Human
Tissue:  HEK293 cells.
Response measured:  Interaction between GPCRs monitored using BRET.
References:  91
Measurement of cAMP levels in HEK-293 cells using a FRET based biosensor.
Species:  Human
Tissue:  HEK293 cells.
Response measured:  cAMP accumulation measured using FRET-based cAMP biosensor.
References:  185
Glucose uptake in skeletal muscle.
Species:  Rat
Tissue:  L6 skeletal muscle cells.
Response measured:  Glucose uptake measured using [3H]2-deoxyglucose.
References:  152
Physiological Functions Click here for help
Hypotension, lowering of blood pressure.
Species:  Mouse
Tissue:  Blood vessels.
References:  46
Presynaptic facilitation of noradrenlaine release from sympathetic nerves.
Species:  Rat
Tissue:  Isolated perfused kidney.
References:  105
Bronchodilation.
Species:  Mouse
Tissue:  Lung.
References:  42
Uterine relaxation.
Species:  Human
Tissue:  Myometrial muscle.
References:  118
Inhibition of apoptosis via a PTX-sensitive G-protein.
Apoptosis via Gs and adenylyl cyclase.
Species:  Rat
Tissue:  Ventricular cardiomyocytes.
References:  145
Stimulation of aqueous humor formation and outflow.
Species:  Human
Tissue:  Eye.
References:  141
Positive inotropic, chronotropic and lusitropic effects in atria.
Species:  Human
Tissue:  Right atrial appendage.
References:  131
All the β-adrenoceptors mediate relaxation of the internal anal sphincter (IAS) smooth muscle, the β2 subtype achieving this via both the Gs/cAMP pathway and the Gi/o/cGMP pathway.
Species:  Rat
Tissue:  Internal anal sphincter (IAS) smooth muscle.
References:  111
Cardioprotective effects.
Species:  Mouse
Tissue:  Cardiomyocytes from mice with chemically induced cardiotoxicity.
References:  33,161
Glucose release from liver.
Species:  Human
Tissue:  Liver.
References:  40,68
Modulation of kidney function in humans and other animals.
Species:  Human
Tissue:  Kidney.
References:  96
Bronchodilation in human and other animals.
Species:  Human
Tissue:  Lung.
References:  186
Synaptic plasticity and memory.
Species:  Mouse
Tissue:  Brain.
References:  49,60,74,90
Coronary vasodilation.
Species:  Human
Tissue:  Coronary blood vessels.
References:  144,184
Glucose uptake in skeletal muscle.
Species:  Rat
Tissue:  L6 skeletal muscle cells.
References:  152
Physiological Consequences of Altering Gene Expression Click here for help
Studies involving mice overexpressing the β2-adrenoceptor show alterations in heart beat and contractile response.
Species:  Human
Tissue: 
Technique:  Transgenesis.
References:  77
Studies involving β2-adrenoceptor knockouts have only shown obvious physiological changes when under cardiovascular stress conditions. This subtype is thought not to be involved in postnatal development but does mediate peripheral vascular resistance and energy metabolism.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  46
Transgenic (TG) mice overexpressing the β2-adrenoceptor in airway smooth muscle exhibit enhanced β2 signalling and an increase in basal cAMP levels. Tracheal rings from the TG mice showed increased relaxation to a β-agonist, and in vivo studies showed resistance to methacholine-induced bronchoconstriction.
Overall, a decrease in bronchial hyperresponsiveness was seen in the TG mice: an anti-asthmatic state.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  122
β1- and β2-adrenoceptor double knockout mice appear to have unaltered basal heart rate, blood pressure and metabolic rate. Stimulation of these receptors by agonists or exercise reveals they exhibit a normal exercise capacity but at a submaximal heart rate.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  150
β2-AR knockout mice show limited T cell autoimmunity in EAE through a mechanism mediated by the suppression of IL-2, IFN-γ, and GM-CSF production via inducible cAMP early repressor (ICER).
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  8
β1-/β2-AR knockout mice show an enhanced inflammatory response to injury, that delayed early muscle regeneration, but enhanced myoblast proliferation later during regeneration to produce a similar functional recovery to controls by 14 days post-injury.
Species:  Mouse
Tissue:  Skeletal muscle.
Technique:  Gene targeting in embryonic stem cells.
References:  47
β2-AR knockout mice do not develop muscle LIM protein cardiomyopathy due to positive modulation of Ca2+ due to removal of inhibitory Gisignaling and increased phosphorylation of troponin I and phospholamban.
Species:  Mouse
Tissue:  Heart.
Technique: 
References:  47
β2-AR knockout mice show preserved cold- and diet-induced adaptive thermogenesis but disrupted glucose homeostasis possibly by accelerating hepatic glucose production and insulin secretion.
Species:  Mouse
Tissue:  Metabolism.
Technique:  Gene targeting in embryonic stem cells.
References:  56
Immune cell-expressed β2-AR play an essential role in regulating the early inflammatory repair response to acute myocardial injury by facilitating cardiac leukocyte infiltration.
Species:  Mouse
Tissue:  Heart.
Technique:  Gene targeting in embryonic stem cells.
References:  66
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0001777 abnormal body temperature regulation PMID: 12161655 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0004945 abnormal bone resorption PMID: 15724149 
Adrb2+|Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2+
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0004945 abnormal bone resorption PMID: 15724149 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0002971 abnormal brown adipose tissue morphology PMID: 12161655 
Adrb1tm1Bkk|Adrb2tm1Bkk Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MP:0001544 abnormal cardiovascular system physiology PMID: 10358009 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0006319 abnormal epididymal fat pad morphology PMID: 10358008 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0002332 abnormal exercise endurance PMID: 10358008 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0001629 abnormal heart rate PMID: 10358008 
Adrb2tm1Kry|Tg(Col1a1-cre)1Kry Adrb2tm1Kry/Adrb2tm1Kry,Tg(Col1a1-cre)1Kry/0
involves: FVB
MGI:3041865  MGI:87938  MP:0003564 abnormal insulin secretion PMID: 19103808 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0005006 abnormal osteoblast physiology PMID: 15724149 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0008396 abnormal osteoclast differentiation PMID: 15724149 
Adrb2+|Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2+
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0008396 abnormal osteoclast differentiation PMID: 15724149 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0004982 abnormal osteoclast morphology PMID: 15724149 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0001541 abnormal osteoclast physiology PMID: 15724149 
Adrb1tm1Bkk|Adrb2tm1Bkk Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MP:0008872 abnormal physiological response to xenobiotic PMID: 10358009 
Adrb1tm1Bkk|Adrb2tm1Bkk Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 10358009 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0001262 decreased body weight PMID: 10358008 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0004993 decreased bone resorption PMID: 15724149 
Adrb2+|Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2+
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0004993 decreased bone resorption PMID: 15724149 
Adrb1tm1Bkk|Adrb2tm1Bkk Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MP:0005140 decreased cardiac muscle contractility PMID: 10358009 
Adrb2tm1Kry|Tg(Col1a1-cre)1Kry Adrb2tm1Kry/Adrb2tm1Kry,Tg(Col1a1-cre)1Kry/0
involves: FVB
MGI:3041865  MGI:87938  MP:0005560 decreased circulating glucose level PMID: 19103808 
Adrb2+|Adrb2tm1Kry|Lep+|Lepob|Tg(Col1a1-cre)1Kry Adrb2tm1Kry/Adrb2+,Lepob/Lep+,Tg(Col1a1-cre)1Kry/0
involves: C57BL/6 * FVB * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:3041865  MGI:87938  MP:0005560 decreased circulating glucose level PMID: 19103808 
Adrb1tm1Bkk|Adrb2tm1Bkk Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MP:0005333 decreased heart rate PMID: 10358009 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0004876 decreased mean systemic arterial blood pressure PMID: 10358008 
Adrb1tm1Bkk|Adrb2tm1Bkk Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MP:0005290 decreased oxygen consumption PMID: 10358009 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0005290 decreased oxygen consumption PMID: 12161655 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0010379 decreased respiratory quotient PMID: 10358008 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0001260 increased body weight PMID: 12161655 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0005605 increased bone mass PMID: 15724149 
Adrb2+|Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2+
involves: 129S1/Sv * 129X1/SvJ
MGI:87938  MP:0005605 increased bone mass PMID: 15724149 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0009119 increased brown fat cell size PMID: 12161655 
Adrb2tm1Kry|Tg(Col1a1-cre)1Kry Adrb2tm1Kry/Adrb2tm1Kry,Tg(Col1a1-cre)1Kry/0
involves: FVB
MGI:3041865  MGI:87938  MP:0002079 increased circulating insulin level PMID: 19103808 
Adrb2+|Adrb2tm1Kry|Lep+|Lepob|Tg(Col1a1-cre)1Kry Adrb2tm1Kry/Adrb2+,Lepob/Lep+,Tg(Col1a1-cre)1Kry/0
involves: C57BL/6 * FVB * STOCK Mlph a Tgfa Cdh23 Ednrb
MGI:104663  MGI:3041865  MGI:87938  MP:0002079 increased circulating insulin level PMID: 19103808 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0005669 increased circulating leptin level PMID: 12161655 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0009294 increased interscapular fat pad weight PMID: 12161655 
Adrb2tm1Bkk Adrb2tm1Bkk/Adrb2tm1Bkk
FVB.129-Adrb2
MGI:87938  MP:0002842 increased systemic arterial blood pressure PMID: 10358008 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0010024 increased total body fat amount PMID: 12161655 
Adrb1tm1Bkk|Adrb2tm1Bkk|Adrb3tm1Lowl Adrb1tm1Bkk/Adrb1tm1Bkk,Adrb2tm1Bkk/Adrb2tm1Bkk,Adrb3tm1Lowl/Adrb3tm1Lowl
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N
MGI:87937  MGI:87938  MGI:87939  MP:0001261 obese PMID: 12161655 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Asthma, susceptibility to
Disease Ontology: DOID:2841
OMIM: 600807
Comments: 
Disease:  Obesity
Disease Ontology: DOID:9970
OMIM: 601665
Role: 
Biologically Significant Variants Click here for help
Type:  Single nucleotide polymorphism
Species:  Mouse
Description:  A Thr164 -> Ile polymorphism has been identified in humans. To understand the physiological consequences of this variant, a study has been undertaken where the Thr164 -> Ile polymorphism is mimicked in transgenic mice. Results showed impaired receptor coupling to adenylyl cyclase in myocardial membranes in vitro and impaired receptor-mediated cardiac function in vivo.
References:  178
Type:  Single nucleotide polymorphism
Species:  Human
Description:  An Arg16 -> Gly polymorphism has been identified in humans, shown to depress receptor function due to increased receptor downregulation. Studies have suggested this variant may influence vasodilator responses through differences in nitric oxide generation. In two populations of non-nocturnal and nocturnal asthmatic patients, the presence of the Arg16 > Gly polymorphism was statistically significantly increased in the nocturnal asthmatic population. This patient population also appeared to be more susceptible to desensitization of the airways to β2-adrenoceptor agonists.
References:  61,81,113,179
Biologically Significant Variant Comments
For a review of the functional and condition-related impacts of β2-AR polymorphisms see reference [2].
General Comments
For a review on the β-adrenoceptor polymorphisms see references [109] and [2].

References

Show »

1. Abraham G, Kneuer C, Ehrhardt C, Honscha W, Ungemach FR. (2004) Expression of functional beta2-adrenergic receptors in the lung epithelial cell lines 16HBE14o(-), Calu-3 and A549. Biochim Biophys Acta, 1691 (2-3): 169-79. [PMID:15110997]

2. Ahles A, Engelhardt S. (2024) Genetic Variants of Adrenoceptors. Handb Exp Pharmacol, 285: 27-54. [PMID:37578621]

3. Ahn S, Kahsai AW, Pani B, Wang QT, Zhao S, Wall AL, Strachan RT, Staus DP, Wingler LM, Sun LD et al.. (2017) Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library. Proc Natl Acad Sci U S A, 114 (7): 1708-1713. [PMID:28130548]

4. Alikhani V, Beer D, Bentley D, Bruce I, Cuenoud BM, Fairhurst RA, Gedeck P, Haberthuer S, Hayden C, Janus D et al.. (2004) Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity. Bioorg Med Chem Lett, 14 (18): 4705-10. [PMID:15324892]

5. Allen JM, Baetge EE, Abrass IB, Palmiter RD. (1988) Isoproterenol response following transfection of the mouse beta 2-adrenergic receptor gene into Y1 cells. EMBO J, 7 (1): 133-8. [PMID:2834198]

6. André C, Erraji L, Gaston J, Grimber G, Briand P, Guillet JG. (1996) Transgenic mice carrying the human beta 2-adrenergic receptor gene with its own promoter overexpress beta 2-adrenergic receptors in liver. Eur J Biochem, 241 (2): 417-24. [PMID:8917438]

7. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M. (2000) Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA, 97 (7): 3684-9. [PMID:10725388]

8. Araujo LP, Maricato JT, Guereschi MG, Takenaka MC, Nascimento VM, de Melo FM, Quintana FJ, Brum PC, Basso AS. (2019) The Sympathetic Nervous System Mitigates CNS Autoimmunity via β2-Adrenergic Receptor Signaling in Immune Cells. Cell Rep, 28 (12): 3120-3130.e5. [PMID:31533035]

9. Aristotelous T, Ahn S, Shukla AK, Gawron S, Sassano MF, Kahsai AW, Wingler LM, Zhu X, Tripathi-Shukla P, Huang XP et al.. (2013) Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Med Chem Lett, 4 (10): 1005-1010. [PMID:24454993]

10. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Piñeyro G. (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA, 100 (20): 11406-11. [PMID:13679574]

11. Baerwald C, Graefe C, Muhl C, Von Wichert P, Krause A. (1992) Beta 2-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatic diseases. Eur J Clin Invest, 22 Suppl 1: 42-6. [PMID:1333966]

12. Baker JG. (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]

13. Baker JG. (2010) The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol, 160 (5): 1048-61. [PMID:20590599]

14. Baker JG. (2026) Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker. Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]

15. Baker JG, Adams LA, Salchow K, Mistry SN, Middleton RJ, Hill SJ, Kellam B. (2011) Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors. J Med Chem, 54 (19): 6874-87. [PMID:21870877]

16. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020) Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers. ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874]

17. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017) Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J, 31 (7): 3150-3166. [PMID:28400472]

18. Baker JG, Hall IP, Hill SJ. (2002) Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor. Br J Pharmacol, 137 (3): 400-8. [PMID:12237261]

19. Baker JG, Hall IP, Hill SJ. (2003) Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666]

20. Baker JG, Hall IP, Hill SJ. (2003) Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol Pharmacol, 64 (3): 679-88. [PMID:12920204]

21. Baker JG, Hall IP, Hill SJ. (2004) Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. Mol Pharmacol, 65 (4): 986-98. [PMID:15044629]

22. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011) Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J, 25 (12): 4486-97. [PMID:21865315]

23. Baker JG, Lim VJY, Proudman RGW, Giese FNZ, Kolb P. (2025) Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor. Mol Pharmacol, 107 (11): 100081. [PMID:41289653]

24. Baker JG, Proudman RG, Hill SJ. (2014) Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Mol Pharmacol, 85 (5): 811-29. [PMID:24608857]

25. Baker JG, Proudman RG, Hill SJ. (2015) Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains. Mol Pharmacol, 87 (1): 103-20. [PMID:25324048]

26. Baker JG, Shaw DE. (2024) Asthma and COPD: A Focus on β-Agonists - Past, Present and Future. Handb Exp Pharmacol, 285: 369-451. [PMID:37709918]

27. Baker JG, Summers RJ. (2024) Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays. Handb Exp Pharmacol, 285: 55-145. [PMID:38926158]

28. Barki-Harrington L, Luttrell LM, Rockman HA. (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation, 108 (13): 1611-8. [PMID:12963634]

29. Basarrate S, Monzel AS, Smith JLM, Marsland AL, Trumpff C, Picard M. (2024) Glucocorticoid and Adrenergic Receptor Distribution Across Human Organs and Tissues: A Map for Stress Transduction. Psychosom Med, 86 (2): 89-98. [PMID:38193786]

30. Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L et al.. (2006) In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther, 317 (2): 762-70. [PMID:16434564]

31. Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D et al.. (2012) An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. Bioorg Med Chem Lett, 22 (19): 6280-5. [PMID:22932315]

32. Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, Matthees ESF, Drube J, Miess-Tanneberg E, Malan D et al.. (2022) How Carvedilol activates β2-adrenoceptors. Nat Commun, 13 (1): 7109. [PMID:36402762]

33. Bernstein D, Fajardo G, Zhao M, Urashima T, Powers J, Berry G, Kobilka BK. (2005) Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol, 289 (6): H2441-9. [PMID:16040722]

34. Berthouze M, Ayoub M, Russo O, Rivail L, Sicsic S, Fischmeister R, Berque-Bestel I, Jockers R, Lezoualc'h F. (2005) Constitutive dimerization of human serotonin 5-HT4 receptors in living cells. FEBS Lett, 579 (14): 2973-80. [PMID:15896782]

35. Billington CK, Penn RB, Hall IP. (2017) β2 Agonists. Handb Exp Pharmacol, 237: 23-40. [PMID:27878470]

36. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A. (2010) Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther, 334 (1): 53-62. [PMID:20371707]

37. Breit A, Lagacé M, Bouvier M. (2004) Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem, 279 (27): 28756-65. [PMID:15123695]

38. Brisinda D, Sorbo AR, Venuti A, Ruggieri MP, Manna R, Fenici P, Wallukat G, Hoebeke J, Frustaci A, Fenici R. (2012) Anti-β-adrenoceptors autoimmunity causing 'idiopathic' arrhythmias and cardiomyopathy. Circ J, 76 (6): 1345-53. [PMID:22447021]

39. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S et al.. (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res, 59 (3): 297-309. [PMID:2876788]

40. Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD. (1998) The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol, 54 (2): 141-7. [PMID:9626918]

41. Buxton BF, Jones CR, Molenaar P, Summers RJ. (1987) Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol, 92 (2): 299-310. [PMID:2823947]

42. Callaerts-Vegh Z, Evans KL, Dudekula N, Cuba D, Knoll BJ, Callaerts PF, Giles H, Shardonofsky FR, Bond RA. (2004) Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA, 101 (14): 4948-53. [PMID:15069206]

43. Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE. (1999) Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther, 290 (2): 649-55. [PMID:10411574]

44. Cao N, Chen H, Bai Y, Yang X, Xu W, Hao W, Zhou Y, Chai J, Wu Y, Wang Z et al.. (2018) β2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β1-adrenergic receptor autoantibodies in heart failure. Cardiovasc Res, 114 (11): 1487-1498. [PMID:29746700]

45. Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD. (2013) Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. Cell Signal, 25 (4): 736-42. [PMID:23291003]

46. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK. (1999) Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem, 274 (24): 16694-700. [PMID:10358008]

47. Church JE, Trieu J, Sheorey R, Chee AY, Naim T, Baum DM, Ryall JG, Gregorevic P, Lynch GS. (2014) Functional β-adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiation. PLoS One, 9 (7): e101379. [PMID:25000590]

48. Cros C, Brette F. (2013) Functional subcellular distribution of β1- and β2-adrenergic receptors in rat ventricular cardiac myocytes. Physiol Rep, 1 (3): e00038. [PMID:24303124]

49. Dang V, Medina B, Das D, Moghadam S, Martin KJ, Lin B, Naik P, Patel D, Nosheny R, Wesson Ashford J et al.. (2014) Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry, 75 (3): 179-88. [PMID:23827853]

50. De Pascali F, Ippolito M, Wolfe E, Komolov KE, Hopfinger N, Lemenze D, Kim N, Armen RS, An SS, Scott CP et al.. (2022) β2 -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the β2 -adrenoceptor with possible implications for the treatment of asthma. Br J Pharmacol, 179 (19): 4692-4708. [PMID:35732075]

51. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020) The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors. Pharmacol Res Perspect, 8 (5): e00643. [PMID:32813332]

52. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. (2000) The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev, 52 (4): 595-638. [PMID:11121511]

53. Elnatan J, Molenaar P, Rosenfeldt FL, Summers RJ. (1994) Autoradiographic localization and quantitation of beta 1- and beta 2-adrenoceptors in the human atrioventricular conducting system: a comparison of patients with idiopathic dilated cardiomyopathy and ischemic heart disease. J Mol Cell Cardiol, 26 (3): 313-23. [PMID:7913135]

54. Erdogan BR, Michel MC, Arioglu-Inan E. (2020) Expression and Signaling of β-Adrenoceptor Subtypes in the Diabetic Heart. Cells, 9 (12). [PMID:33256212]

55. Evans BA, Merlin J, Bengtsson T, Hutchinson DS. (2019) Adrenoceptors in white, brown, and brite adipocytes. Br J Pharmacol, 176 (14): 2416-2432. [PMID:30801689]

56. Fernandes GW, Ueta CB, Fonseca TL, Gouveia CH, Lancellotti CL, Brum PC, Christoffolete MA, Bianco AC, Ribeiro MO. (2014) Inactivation of the adrenergic receptor β2 disrupts glucose homeostasis in mice. J Endocrinol, 221 (3): 381-90. [PMID:24868110]

57. Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. (1988) Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. Proc Natl Acad Sci USA, 85 (24): 9494-8. [PMID:2849109]

58. Gálvez I, Martín-Cordero L, Hinchado MD, Álvarez-Barrientos A, Ortega E. (2019) Anti-inflammatory effect of β2 adrenergic stimulation on circulating monocytes with a pro-inflammatory state in high-fat diet-induced obesity. Brain Behav Immun, 80: 564-572. [PMID:31055173]

59. Galaz-Montoya M, Wright SJ, Rodriguez GJ, Lichtarge O, Wensel TG. (2017) β2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem, 292 (24): 9967-9974. [PMID:28442571]

60. Gao V, Suzuki A, Magistretti PJ, Lengacher S, Pollonini G, Steinman MQ, Alberini CM. (2016) Astrocytic β2-adrenergic receptors mediate hippocampal long-term memory consolidation. Proc Natl Acad Sci U S A, 113 (30): 8526-31. [PMID:27402767]

61. Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. (2003) Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol (Lond.), 546 (Pt 2): 583-9. [PMID:12527744]

62. Giordani L, Cuzziol N, Del Pinto T, Sanchez M, Maccari S, Massimi A, Pietraforte D, Viora M. (2015) β2-Agonist clenbuterol hinders human monocyte differentiation into dendritic cells. Exp Cell Res, 339 (2): 163-73. [PMID:26524508]

63. Gocayne J, Robinson DA, FitzGerald MG, Chung FZ, Kerlavage AR, Lentes KU, Lai J, Wang CD, Fraser CM, Venter JC. (1987) Primary structure of rat cardiac beta-adrenergic and muscarinic cholinergic receptors obtained by automated DNA sequence analysis: further evidence for a multigene family. Proc Natl Acad Sci USA, 84 (23): 8296-300. [PMID:2825184]

64. Golf S, Løvstad R, Hansson V. (1985) Beta-adrenoceptor density and relative number of beta-adrenoceptor subtypes in biopsies from human right atrial, left ventricular, and right ventricular myocard. Cardiovasc Res, 19 (10): 636-41. [PMID:2996771]

65. Gorelik J, Wright PT, Lyon AR, Harding SE. (2013) Spatial control of the βAR system in heart failure: the transverse tubule and beyond. Cardiovasc Res, 98 (2): 216-24. [PMID:23345264]

66. Grisanti LA, Gumpert AM, Traynham CJ, Gorsky JE, Repas AA, Gao E, Carter RL, Yu D, Calvert JW, García AP et al.. (2016) Leukocyte-Expressed β2-Adrenergic Receptors Are Essential for Survival After Acute Myocardial Injury. Circulation, 134 (2): 153-67. [PMID:27364164]

67. Guereschi MG, Araujo LP, Maricato JT, Takenaka MC, Nascimento VM, Vivanco BC, Reis VO, Keller AC, Brum PC, Basso AS. (2013) Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol, 43 (4): 1001-12. [PMID:23436577]

68. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. (2000) Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax, 55 (8): 650-6. [PMID:10899240]

69. Guo Q, He B, Zhong Y, Jiao H, Ren Y, Wang Q, Ge Q, Gao Y, Liu X, Du Y et al.. (2024) A method for structure determination of GPCRs in various states. Nat Chem Biol, 20 (1): 74-82. [PMID:37580554]

70. Haack KK, Tougas MR, Jones KT, El-Dahr SS, Radhakrishna H, McCarty NA. (2010) A novel bioassay for detecting GPCR heterodimerization: transactivation of beta 2 adrenergic receptor by bradykinin receptor. J Biomol Screen, 15 (3): 251-60. [PMID:20150590]

71. Hague C, Uberti MA, Chen Z, Bush CF, Jones SV, Ressler KJ, Hall RA, Minneman KP. (2004) Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor. Proc Natl Acad Sci USA, 101 (37): 13672-6. [PMID:15347813]

72. Haley JM, Thackeray JT, Thorn SL, DaSilva JN. (2015) Cardiac β-Adrenoceptor Expression Is Reduced in Zucker Diabetic Fatty Rats as Type-2 Diabetes Progresses. PLoS One, 10 (5): e0127581. [PMID:25996498]

73. Ham S, Mukaida S, Sato M, Keov P, Bengtsson T, Furness S, Holliday ND, Evans BA, Summers RJ, Hutchinson DS. (2024) Role of G protein-coupled receptor kinases (GRKs) in β2 -adrenoceptor-mediated glucose uptake. Pharmacol Res Perspect, 12 (1): e1176. [PMID:38332691]

74. Havekes R, Canton DA, Park AJ, Huang T, Nie T, Day JP, Guercio LA, Grimes Q, Luczak V, Gelman IH et al.. (2012) Gravin orchestrates protein kinase A and β2-adrenergic receptor signaling critical for synaptic plasticity and memory. J Neurosci, 32 (50): 18137-49. [PMID:23238728]

75. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem, 271 (27): 16384-92. [PMID:8663163]

76. Hervé J, Dubreil L, Tardif V, Terme M, Pogu S, Anegon I, Rozec B, Gauthier C, Bach JM, Blancou P. (2013) β2-Adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells. J Immunol, 190 (7): 3163-71. [PMID:23420884]

77. Heubach JF, Trebess I, Wettwer E, Himmel HM, Michel MC, Kaumann AJ, Koch WJ, Harding SE, Ravens U. (1999) L-type calcium current and contractility in ventricular myocytes from mice overexpressing the cardiac beta 2-adrenoceptor. Cardiovasc Res, 42 (1): 173-82. [PMID:10435008]

78. Hoenke C, Bouyssou T, Tautermann CS, Rudolf K, Schnapp A, Konetzki I. (2009) Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists. Bioorg Med Chem Lett, 19 (23): 6640-4. [PMID:19875286]

79. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 369 (2): 151-9. [PMID:14730417]

80. Hohberger B, Kunze R, Wallukat G, Kara K, Mardin CY, Lämmer R, Schlötzer-Schrehardt U, Hosari S, Horn F, Munoz L et al.. (2019) Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma. Front Immunol, 10: 2112. [PMID:31632387]

81. Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. (2000) beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J, 139 (3): 537-42. [PMID:10689270]

82. Hou DY, Xu L, Zhang ZY, Xu XR, Wang X, Zhang J, Liu JM, Wang H, Chen J, Zhang L. (2020) Clinical value of detecting autoantibodies against β1-, β2,- and α1-adrenergic receptors in carvedilol treatment of patients with heart failure. J Geriatr Cardiol, 17 (6): 305-312. [PMID:32670360]

83. Hudson BD, Hébert TE, Kelly ME. (2010) Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol, 160 (3): 627-42. [PMID:20590567]

84. Imai S, Yokomizo T, Kofuku Y, Shiraishi Y, Ueda T, Shimada I. (2020) Structural equilibrium underlying ligand-dependent activation of β2-adrenoreceptor. Nat Chem Biol, 16 (4): 430-439. [PMID:31959965]

85. Ippolito M, De Pascali F, Inoue A, Benovic JL. (2022) Phenylalanine 193 in Extracellular Loop 2 of the β 2-Adrenergic Receptor Coordinates β-Arrestin Interaction. Mol Pharmacol, 101 (2): 87-94. [PMID:34853152]

86. Ishchenko A, Stauch B, Han GW, Batyuk A, Shiriaeva A, Li C, Zatsepin N, Weierstall U, Liu W, Nango E et al.. (2019) Toward G protein-coupled receptor structure-based drug design using X-ray lasers. IUCrJ, 6 (Pt 6): 1106-1119. [PMID:31709066]

87. Isogaya M, Sugimoto Y, Tanimura R, Tanaka R, Kikkawa H, Nagao T, Kurose H. (1999) Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists. Mol Pharmacol, 56 (5): 875-85. [PMID:10531390]

88. Izeboud CA, Vermeulen RM, Zwart A, Voss HP, van Miert AS, Witkamp RF. (2000) Stereoselectivity at the beta2-adrenoceptor on macrophages is a major determinant of the anti-inflammatory effects of beta2-agonists. Naunyn Schmiedebergs Arch Pharmacol, 362 (2): 184-9. [PMID:10961382]

89. January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, Barber R, Clark RB. (1997) beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem, 272 (38): 23871-9. [PMID:9295336]

90. Jensen CJ, Demol F, Bauwens R, Kooijman R, Massie A, Villers A, Ris L, De Keyser J. (2016) Astrocytic β2 Adrenergic Receptor Gene Deletion Affects Memory in Aged Mice. PLoS One, 11 (10): e0164721. [PMID:27776147]

91. Johnstone EKM, See HB, Abhayawardana RS, Song A, Rosengren KJ, Hill SJ, Pfleger KDG. (2021) Investigation of Receptor Heteromers Using NanoBRET Ligand Binding. Int J Mol Sci, 22 (3). [PMID:33499147]

92. Joiner ML, Lisé MF, Yuen EY, Kam AY, Zhang M, Hall DD, Malik ZA, Qian H, Chen Y, Ulrich JD et al.. (2010) Assembly of a beta2-adrenergic receptor--GluR1 signalling complex for localized cAMP signalling. EMBO J, 29 (2): 482-95. [PMID:19942860]

93. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. (2001) Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA, 98 (1): 343-8. [PMID:11134510]

94. Joyce JN, Lexow N, Kim SJ, Artymyshyn R, Senzon S, Lawrence D, Cassanova MF, Kleinman JE, Bird ED, Winokur A. (1992) Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics. Synapse, 10 (3): 228-46. [PMID:1313605]

95. Kalinovich A, Dehvari N, Åslund A, van Beek S, Halleskog C, Olsen J, Forsberg E, Zacharewicz E, Schaart G, Rinde M et al.. (2020) Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia, 63 (8): 1603-1615. [PMID:32472192]

96. Kamiar A, Yousefi K, Dunkley JC, Webster KA, Shehadeh LA. (2021) β2-Adrenergic receptor agonism as a therapeutic strategy for kidney disease. Am J Physiol Regul Integr Comp Physiol, 320 (5): R575-R587. [PMID:33565369]

97. Kern C, Meyer T, Droux S, Schollmeyer D, Miculka C. (2009) Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol. J Med Chem, 52 (6): 1773-7. [PMID:19245211]

98. Kim YS, Sainz RD, Molenaar P, Summers RJ. (1991) Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles. Biochem Pharmacol, 42 (9): 1783-9. [PMID:1681810]

99. Kim YS, Sainz RD, Summers RJ, Molenaar P. (1992) Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles. J Anim Sci, 70 (1): 115-22. [PMID:1374751]

100. Kim-Fuchs C, Le CP, Pimentel MA, Shackleford D, Ferrari D, Angst E, Hollande F, Sloan EK. (2014) Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun, 40: 40-7. [PMID:24650449]

101. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ. (1987) cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA, 84 (1): 46-50. [PMID:3025863]

102. Krushinski Jr JH, Schaus JM, Thompson DC, Calligaro DO, Nelson DL, Luecke SH, Wainscott DB, Wong DT. (2007) Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett, 17 (20): 5600-4. [PMID:17804228]

103. Kuravi S, Lan TH, Barik A, Lambert NA. (2010) Third-party bioluminescence resonance energy transfer indicates constitutive association of membrane proteins: application to class a g-protein-coupled receptors and g-proteins. Biophys J, 98 (10): 2391-9. [PMID:20483349]

104. Løfling LL, Støer NC, Sloan EK, Chang A, Gandini S, Ursin G, Botteri E. (2022) β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. Br J Cancer, 127 (6): 1086-1096. [PMID:35725814]

105. Lakhlani PP, Amenta F, Napoleone P, Felici L, Eikenburg DC. (1994) Pharmacological characterization and anatomical localization of prejunctional beta-adrenoceptors in the rat kidney. Br J Pharmacol, 111: 1296-1308. [PMID:8032617]

106. LaRocca TJ, Schwarzkopf M, Altman P, Zhang S, Gupta A, Gomes I, Alvin Z, Champion HC, Haddad G, Hajjar RJ et al.. (2010) β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol, 56 (5): 548-59. [PMID:20729750]

107. Lavoie C, Hébert TE. (2003) Pharmacological characterization of putative beta1-beta2-adrenergic receptor heterodimers. Can J Physiol Pharmacol, 81 (2): 186-95. [PMID:12710533]

108. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M et al.. (2002) Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem, 277 (38): 35402-10. [PMID:12140284]

109. Leineweber K, Büscher R, Bruck H, Brodde OE. (2004) Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol, 369 (1): 1-22. [PMID:14647973]

110. Lewis RJ, Chachi L, Newby C, Amrani Y, Bradding P. (2016) Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors. J Immunol, 196 (1): 55-63. [PMID:26608913]

111. Li F, De Godoy M, Rattan S. (2004) Role of adenylate and guanylate cyclases in beta1-, beta2-, and beta3-adrenoceptor-mediated relaxation of internal anal sphincter smooth muscle. J Pharmacol Exp Ther, 308 (3): 1111-20. [PMID:14711933]

112. Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. (2023) The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor. Mol Pharmacol, 103 (2): 89-99. [PMID:36351797]

113. Lima JJ. (2014) Do genetic polymorphisms alter patient response to inhaled bronchodilators?. Expert Opin Drug Metab Toxicol, 10 (9): 1231-40. [PMID:25102170]

114. Liu X, Ahn S, Kahsai AW, Meng KC, Latorraca NR, Pani B, Venkatakrishnan AJ, Masoudi A, Weis WI, Dror RO et al.. (2017) Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure. Nature, 548 (7668): 480-484. [PMID:28813418]

115. Liu X, Kaindl J, Korczynska M, Stößel A, Dengler D, Stanek M, Hübner H, Clark MJ, Mahoney J, Matt RA et al.. (2020) An allosteric modulator binds to a conformational hub in the β2 adrenergic receptor. Nat Chem Biol, 16 (7): 749-755. [PMID:32483378]

116. Liu X, Masoudi A, Kahsai AW, Huang LY, Pani B, Staus DP, Shim PJ, Hirata K, Simhal RK, Schwalb AM et al.. (2019) Mechanism of β2AR regulation by an intracellular positive allosteric modulator. Science, 364 (6447): 1283-1287. [PMID:31249059]

117. Liu Y, Liang X, Ren WW, Li BM. (2014) Expression of β1- and β2-adrenoceptors in different subtypes of interneurons in the medial prefrontal cortex of mice. Neuroscience, 257: 149-57. [PMID:24215978]

118. Liu YL, Nwosu UC, Rice PJ. (1998) Relaxation of isolated human myometrial muscle by beta2-adrenergic receptors but not beta1-adrenergic receptors. Am J Obstet Gynecol, 179 (4): 895-8. [PMID:9790366]

119. Louis SN, Nero TL, Iakovidis D, Jackman GP, Louis WJ. (1999) LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol, 367 (2-3): 431-5. [PMID:10079020]

120. Matt RA, Martin RS, Evans AK, Gever JR, Vargas GA, Shamloo M, Ford AP. (2024) Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease. Handb Exp Pharmacol, 285: 555-616. [PMID:37495851]

121. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, Luttrell LM. (2000) The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem, 275 (13): 9572-80. [PMID:10734107]

122. McGraw DW, Forbes SL, Kramer LA, Witte DP, Fortner CN, Paul RJ, Liggett SB. (1999) Transgenic overexpression of beta(2)-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity. J Biol Chem, 274 (45): 32241-7. [PMID:10542262]

123. McGraw DW, Mihlbachler KA, Schwarb MR, Rahman FF, Small KM, Almoosa KF, Liggett SB. (2006) Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest, 116 (5): 1400-9. [PMID:16670773]

124. McLeod AA, Stiles GL, Shand DG. (1984) Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther, 228 (2): 461-6. [PMID:6141285]

125. McVey M, Ramsay D, Kellett E, Rees S, Wilson S, Pope AJ, Milligan G. (2001) Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta -opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J Biol Chem, 276 (17): 14092-9. [PMID:11278447]

126. Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M. (2002) Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem, 277 (47): 44925-31. [PMID:12244098]

127. Michel MC, Seifert R. (2015) Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. Am J Physiol, Cell Physiol, 308 (7): C505-20. [PMID:25631871]

128. Minneman KP, Hegstrand LR, Molinoff PB. (1979) The pharmacological specificity of beta-1 and beta-2 adrenergic receptors in rat heart and lung in vitro. Mol Pharmacol, 16 (1): 21-33. [PMID:39243]

129. Mistry SN, Baker JG, Fischer PM, Hill SJ, Gardiner SM, Kellam B. (2013) Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists. J Med Chem, 56 (10): 3852-65. [PMID:23614528]

130. Molenaar P, Sarsero D, Arch JR, Kelly J, Henson SM, Kaumann AJ. (1997) Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Br J Pharmacol, 120 (2): 165-76. [PMID:9117106]

131. Molenaar P, Savarimuthu SM, Sarsero D, Chen L, Semmler AB, Carle A, Yang I, Bartel S, Vetter D, Beyerdörfer I et al.. (2007) (-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol, 375 (1): 11-28. [PMID:17295024]

132. Motso A, Pelcman B, Kalinovich A, Kahlous NA, Bokhari MH, Dehvari N, Halleskog C, Waara E, de Jong J, Cheesman E et al.. (2025) GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell, 188 (19): 5142-5156.e23. [PMID:40555230]

133. Mukaida S, Sato M, Öberg AI, Dehvari N, Olsen JM, Kocan M, Halls ML, Merlin J, Sandström AL, Csikasz RI et al.. (2019) BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization. Am J Physiol Regul Integr Comp Physiol, 316 (5): R666-R677. [PMID:30892909]

134. Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. (2014) Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors. J Exp Med, 211 (13): 2583-98. [PMID:25422496]

135. Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C. (2016) Comparison of the β-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions. J Pharmacol Exp Ther, 359 (1): 73-81. [PMID:27451411]

136. Nevzorova J, Bengtsson T, Evans BA, Summers RJ. (2002) Characterization of the beta-adrenoceptor subtype involved in mediation of glucose transport in L6 cells. Br J Pharmacol, 137 (1): 9-18. [PMID:12183326]

137. Nevzorova J, Evans BA, Bengtsson T, Summers RJ. (2006) Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. Br J Pharmacol, 147 (4): 446-54. [PMID:16415914]

138. Pani B, Ahn S, Rambarat PK, Vege S, Kahsai AW, Liu A, Valan BN, Staus DP, Costa T, Lefkowitz RJ. (2021) Unique Positive Cooperativity Between the β-Arrestin-Biased β-Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the β2-Adrenergic Receptor. Mol Pharmacol, 100 (5): 513-525. [PMID:34580163]

139. Pazos A, Probst A, Palacios JM. (1985) Beta-adrenoceptor subtypes in the human brain: autoradiographic localization. Brain Res, 358 (1-2): 324-8. [PMID:3000516]

140. Pietri-Rouxel F, Strosberg AD. (1995) Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol, 9 (3): 211-8. [PMID:7557816]

141. Potter DE. (1981) Adrenergic pharmacology of aqueous humor dynamics. Pharmacol Rev, 33 (3): 133-53. [PMID:7323134]

142. Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Box PC, Butchers PR, Coe DM, Conroy R, Emmons A, Ford AJ et al.. (2010) Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem, 53 (11): 4522-30. [PMID:20462258]

143. Proudman RGW, Baker JG. (2025) A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD. Pharmacol Res Perspect, 13 (5): e70154. [PMID:40887869]

144. Puri R, Liew GY, Nicholls SJ, Nelson AJ, Leong DP, Carbone A, Copus B, Wong DT, Beltrame JF, Worthley SG et al.. (2012) Coronary β2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. Eur Heart J, 33 (4): 495-504. [PMID:21951627]

145. Pönicke K, Heinroth-Hoffmann I, Brodde OE. (2003) Role of beta 1- and beta 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol, 367 (6): 592-9. [PMID:12750877]

146. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS et al.. (2011) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature, 469 (7329): 175-80. [PMID:21228869]

147. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF et al.. (2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature, 450 (7168): 383-7. [PMID:17952055]

148. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D et al.. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature, 477 (7366): 549-55. [PMID:21772288]

149. Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK. (2013) Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature, 502 (7472): 575-579. [PMID:24056936]

150. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK. (1999) Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem, 274 (24): 16701-8. [PMID:10358009]

151. Russo-Neustadt A, Cotman CW. (1997) Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J Neurosci, 17 (14): 5573-80. [PMID:9204938]

152. Sato M, Dehvari N, Oberg AI, Dallner OS, Sandström AL, Olsen JM, Csikasz RI, Summers RJ, Hutchinson DS, Bengtsson T. (2014) Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes, 63 (12): 4115-29. [PMID:25008179]

153. Sato T, Baker J, Warne T, Brown GA, Leslie AG, Congreve M, Tate CG. (2015) Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound β1-Adrenergic Receptor. Mol Pharmacol, 88 (6): 1024-34. [PMID:26385885]

154. Sato Y, Kurose H, Isogaya M, Nagao T. (1996) Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Eur J Pharmacol, 315 (3): 363-7. [PMID:8982677]

155. Scharf MM, Bünemann M, Baker JG, Kolb P. (2019) Comparative Docking to Distinct G Protein-Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy. Mol Pharmacol, 96 (6): 851-861. [PMID:31624135]

156. Seifert R, Lee TW, Lam VT, Kobilka BK. (1998) Reconstitution of beta2-adrenoceptor-GTP-binding-protein interaction in Sf9 cells--high coupling efficiency in a beta2-adrenoceptor-G(s alpha) fusion protein. Eur J Biochem, 255 (2): 369-82. [PMID:9716378]

157. Sharma D, Farrar JD. (2020) Adrenergic regulation of immune cell function and inflammation. Semin Immunopathol, 42 (6): 709-717. [PMID:33219396]

158. Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, Knowles RG. (2013) In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther, 344 (1): 218-30. [PMID:23131596]

159. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L et al.. (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res, 70 (18): 7042-52. [PMID:20823155]

160. Smith C, Teitler M. (1999) Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther, 13 (2): 123-6. [PMID:10372227]

161. Song Y, Xu C, Liu J, Li Y, Wang H, Shan D, Wainer IW, Hu X, Zhang Y, Woo AY et al.. (2021) Heterodimerization With 5-HT2BR Is Indispensable for β2AR-Mediated Cardioprotection. Circ Res, 128 (2): 262-277. [PMID:33208036]

162. Soriano-Ursúa MA, McNaught-Flores DA, Nieto-Alamilla G, Segura-Cabrera A, Correa-Basurto J, Arias-Montaño JA, Trujillo-Ferrara JG. (2012) Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor. Bioorg Med Chem, 20 (2): 933-41. [PMID:22182578]

163. Staus DP, Strachan RT, Manglik A, Pani B, Kahsai AW, Kim TH, Wingler LM, Ahn S, Chatterjee A, Masoudi A et al.. (2016) Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature, 535 (7612): 448-52. [PMID:27409812]

164. Stiles GL, Caron MG, Lefkowitz RJ. (1984) Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev, 64 (2): 661-743. [PMID:6143332]

165. Stiles GL, Taylor S, Lefkowitz RJ. (1983) Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci, 33 (5): 467-73. [PMID:6135968]

166. Stipp R, Bertrand Q, Trabuco M, Duran-Corbera A, Ignazzitto MT, Glover H, Stierli F, Catena J, Carrillo M, Hartmann S et al.. (2026) Structural Mechanism of an Efficacy Photoswitch Targeting the β2-adrenergic Receptor. Angew Chem Int Ed Engl, 65 (18): e17995. [PMID:41848496]

167. Strosberg AD. (1997) Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260]

168. Sugimoto Y, Fujisawa R, Tanimura R, Lattion AL, Cotecchia S, Tsujimoto G, Nagao T, Kurose H. (2002) Beta(1)-selective agonist (-)-1-(3,4-dimethoxyphenetylamino)-3-(3,4-dihydroxy)-2-propanol [(-)-RO363] differentially interacts with key amino acids responsible for beta(1)-selective binding in resting and active states. J Pharmacol Exp Ther, 301 (1): 51-8. [PMID:11907156]

169. Summers RJ, Molnaar P, Russell F, Elnatan J, Jones CR, Buxton BF, Chang V, Hambley J. (1989) Coexistence and localization of beta 1- and beta 2-adrenoceptors in the human heart. Eur Heart J, 10 Suppl B: 11-21. [PMID:2553407]

170. Susec M, Sencanski M, Glisic S, Veljkovic N, Pedersen C, Drinovec L, Stojan J, Nøhr J, Vrecl M. (2019) Functional characterization of β2-adrenergic and insulin receptor heteromers. Neuropharmacology, 152: 78-89. [PMID:30707913]

171. Swaminath G, Lee TW, Kobilka B. (2003) Identification of an allosteric binding site for Zn2+ on the beta2 adrenergic receptor. J Biol Chem, 278 (1): 352-6. [PMID:12409304]

172. Swaminath G, Steenhuis J, Kobilka B, Lee TW. (2002) Allosteric modulation of beta2-adrenergic receptor by Zn(2+). Mol Pharmacol, 61 (1): 65-72. [PMID:11752207]

173. Sykes DA, Charlton SJ. (2012) Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists. Br J Pharmacol, 165 (8): 2672-83. [PMID:21883146]

174. Sykes DA, Jiménez-Rosés M, Reilly J, Fairhurst RA, Charlton SJ, Veprintsev DB. (2022) Exploring the kinetic selectivity of drugs targeting the β1 -adrenoceptor. Pharmacol Res Perspect, 10 (4): e00978. [PMID:35762357]

175. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther, 321 (2): 642-7. [PMID:17293563]

176. Tanner MA, Maitz CA, Grisanti LA. (2021) Immune cell β2-adrenergic receptors contribute to the development of heart failure. Am J Physiol Heart Circ Physiol, 321 (4): H633-H649. [PMID:34415184]

177. Tricomi J, Landini L, Nieddu V, Cavallaro U, Baker JG, Papakyriakou A, Richichi B. (2023) Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships. Eur J Med Chem, 246: 114961. [PMID:36495629]

178. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. (1996) Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA, 93 (19): 10483-8. [PMID:8816827]

179. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. (1995) Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest, 95 (4): 1635-41. [PMID:7706471]

180. Uberti MA, Hague C, Oller H, Minneman KP, Hall RA. (2005) Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. J Pharmacol Exp Ther, 313 (1): 16-23. [PMID:15615865]

181. Udumyan R, Montgomery S, Fang F, Almroth H, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K. (2017) Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. Cancer Res, 77 (13): 3700-3707. [PMID:28473530]

182. Uehling DE, Shearer BG, Donaldson KH, Chao EY, Deaton DN, Adkison KK, Brown KK, Cariello NF, Faison WL, Lancaster ME et al.. (2006) Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. J Med Chem, 49 (9): 2758-71. [PMID:16640337]

183. Vago T, Bevilacqua M, Dagani R, Meroni R, Frigeni G, Santoliss C, Norbiato G. (1984) Comparison of rat and human left ventricle beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Biochem Biophys Res Commun, 121 (1): 346-54. [PMID:6329198]

184. Vargas Pelaez AF, Gao Z, Ahmad TA, Leuenberger UA, Proctor DN, Maman SR, Muller MD. (2016) Effect of adrenergic agonists on coronary blood flow: a laboratory study in healthy volunteers. Physiol Rep, 4 (10). [PMID:27225628]

185. Vedel L, Bräuner-Osborne H, Mathiesen JM. (2015) A cAMP Biosensor-Based High-Throughput Screening Assay for Identification of Gs-Coupled GPCR Ligands and Phosphodiesterase Inhibitors. J Biomol Screen, 20 (7): 849-57. [PMID:25851033]

186. Wendell SG, Fan H, Zhang C. (2020) G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. Pharmacol Rev, 72 (1): 1-49. [PMID:31767622]

187. Wenzel-Seifert K, Liu HY, Seifert R. (2002) Similarities and differences in the coupling of human beta1- and beta2-adrenoceptors to Gs(alpha) splice variants. Biochem Pharmacol, 64 (1): 9-20. [PMID:12106601]

188. Werner C, Müller N, Müller UA. (2019) Agonistic autoantibodies against B2-adrenergic receptors correlating with macrovascular disease in longstanding diabetes type 2. Acta Diabetol, 56 (6): 659-665. [PMID:30770998]

189. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ. (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A, 104 (42): 16657-62. [PMID:17925438]

190. Woo AY, Song Y, Xiao RP, Zhu W. (2015) Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol, 172 (23): 5444-56. [PMID:25298054]

191. Wright PT, Gorelik J, Harding SE. (2021) Electrophysiological Remodeling: Cardiac T-Tubules and ß-Adrenoceptors. Cells, 10 (9). [PMID:34572106]

192. Wrzal PK, Devost D, Pétrin D, Goupil E, Iorio-Morin C, Laporte SA, Zingg HH, Hébert TE. (2012) Allosteric interactions between the oxytocin receptor and the β2-adrenergic receptor in the modulation of ERK1/2 activation are mediated by heterodimerization. Cell Signal, 24 (1): 342-50. [PMID:21963428]

193. Wrzal PK, Goupil E, Laporte SA, Hébert TE, Zingg HH. (2012) Functional interactions between the oxytocin receptor and the β2-adrenergic receptor: implications for ERK1/2 activation in human myometrial cells. Cell Signal, 24 (1): 333-41. [PMID:21964067]

194. Xu X, Shonberg J, Kaindl J, Clark MJ, Stößel A, Maul L, Mayer D, Hübner H, Hirata K, Venkatakrishnan AJ et al.. (2023) Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics. Nat Commun, 14 (1): 2138. [PMID:37059717]

195. Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. (2023) Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. PLoS One, 18 (9): e0290685. [PMID:37656760]

196. Yatani A, Tajima Y, Green SA. (1999) Coupling of beta-adrenergic receptors to cardiac L-type Ca2+ channels: preferential coupling of the beta1 versus beta2 receptor subtype and evidence for PKA-independent activation of the channel. Cell Signal, 11 (5): 337-42. [PMID:10376806]

197. Zhu WZ, Chakir K, Zhang S, Yang D, Lavoie C, Bouvier M, Hébert TE, Lakatta EG, Cheng H, Xiao RP. (2005) Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res, 97 (3): 244-51. [PMID:16002745]

Contributors

Show »

How to cite this target page

The citation format for the published version of this page will be: